Summit Therapeutics, Inc
TubeHealth is an independent service and is not affiliated with or endorsed by YouTube or Google.
Data displayed on this page is retrieved via YouTube API Services.
Updated:
Summit Therapeutics, Inc Channel Description Snapshot
Channel Description
Summit’s Mission: To resolve serious, unmet medical needs in oncology for the betterment of overall human health.
Summit’s lead molecule, ivonescimab,* known as SMT112 in the United States, Canada, Europe, and Japan (Summit’s license territories), and as AK112 in China and Australia, is a bispecific antibody combining the effects of immunotherapy via anti-PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays cooperative binding to its intended targets with higher affinity when in the presence of PD-1 & VEGF. Ivonescimab was discovered by Akeso, Inc. (HKEX Code: 9926.HK)
Summit is enrolling two Phase III clinical trials in Non-small Cell Lung Cancer (NSCLC): NCT05184712/NCT05899608. Globally 1,600+ patients have been treated with ivonescimab across all clinical trials conducted by Akeso and Summit.
*Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
All Rights Reserved.
Summit’s lead molecule, ivonescimab,* known as SMT112 in the United States, Canada, Europe, and Japan (Summit’s license territories), and as AK112 in China and Australia, is a bispecific antibody combining the effects of immunotherapy via anti-PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays cooperative binding to its intended targets with higher affinity when in the presence of PD-1 & VEGF. Ivonescimab was discovered by Akeso, Inc. (HKEX Code: 9926.HK)
Summit is enrolling two Phase III clinical trials in Non-small Cell Lung Cancer (NSCLC): NCT05184712/NCT05899608. Globally 1,600+ patients have been treated with ivonescimab across all clinical trials conducted by Akeso and Summit.
*Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
All Rights Reserved.
About This Page
Methodology: This page displays a snapshot of publicly available creator information retrieved via YouTube API Services.
Snapshot
Snapshot Date:
Data Source: Public data retrieved via YouTube API Services
Data is refreshed at least once every 30 days.